RecruitingNot Applicable

Introduction of ACI for Cartilage Repair

Switzerland218 participantsStarted 2017-09-01

Plain-language summary

This study was aimed to evaluate effectiveness and safety of autologous chondrocyte suspension for treatment of knee articular cartilage defects.

Who can participate

Age range

15 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age between 15 and 50.
. Lesions classified as ICRS Grade III or IV and smaller than 15 cm2
. Lesions that have failed prior therapy (conservative or surgical treatment ≥ six months)
. Subjects who understand and sign the consent form for this study

Exclusion criteria

. Body mass index (BMI) of 35 or more
. Osteoarthritis or rheumatoid arthritis
. Diffuse lesion
. Uncorrected mal-alignment, ligamentous instability, or meniscal tear
. Presence of growth cartilage (15-18 years old)
. Active smoking or drug consumption
. Women who are pregnant
. Positive serology for HIV-1 or HIV-2, Hepatitis B and C and syphilis

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Rate of implantation-associated complications: serious adverse events (SAEs) and serious adverse reactions (SARs)

Timeframe: Up to 12 months.

Change in tissue integrity into and around the treated aera

Timeframe: 3 months post-implantation

Absence of infection after implantation.

Timeframe: 6 weeks post-implantation

Trial details

NCT IDNCT04296487

SponsorCentre Hospitalier Universitaire Vaudois

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-09

Contact for this trial

Robin MARTIN, MD

021 314 76 79 robin.martin@chuv.ch

View on ClinicalTrials.gov More Articular Cartilage Defect trials